ES2572001T3 - Derivado de bisfurano antivírico como inhibidor de la proteasa del VIH e intermedios del mismo - Google Patents

Derivado de bisfurano antivírico como inhibidor de la proteasa del VIH e intermedios del mismo

Info

Publication number
ES2572001T3
ES2572001T3 ES12192910T ES12192910T ES2572001T3 ES 2572001 T3 ES2572001 T3 ES 2572001T3 ES 12192910 T ES12192910 T ES 12192910T ES 12192910 T ES12192910 T ES 12192910T ES 2572001 T3 ES2572001 T3 ES 2572001T3
Authority
ES
Spain
Prior art keywords
bisfuran
antiviral
intermediates
derived
protease inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12192910T
Other languages
English (en)
Inventor
Kenneth R Crawford
Eric D Dowdy
Arnold Gutierrez
Richard P Polniaszek
Richard Hung Chiu Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ES2572001T3 publication Critical patent/ES2572001T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/42—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/38—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reaction of ammonia or amines with sulfonic acids, or with esters, anhydrides, or halides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4084—Esters with hydroxyaryl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un compuesto que tiene la fórmula C:**Fórmula** o una sal farmacéuticamente aceptable del mismo.
ES12192910T 2006-03-29 2007-03-29 Derivado de bisfurano antivírico como inhibidor de la proteasa del VIH e intermedios del mismo Active ES2572001T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78712606P 2006-03-29 2006-03-29

Publications (1)

Publication Number Publication Date
ES2572001T3 true ES2572001T3 (es) 2016-05-27

Family

ID=38323963

Family Applications (2)

Application Number Title Priority Date Filing Date
ES07754134T Active ES2430557T3 (es) 2006-03-29 2007-03-29 Proceso para la preparación de inhibidores de la proteasa del VIH
ES12192910T Active ES2572001T3 (es) 2006-03-29 2007-03-29 Derivado de bisfurano antivírico como inhibidor de la proteasa del VIH e intermedios del mismo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES07754134T Active ES2430557T3 (es) 2006-03-29 2007-03-29 Proceso para la preparación de inhibidores de la proteasa del VIH

Country Status (24)

Country Link
US (4) US8173623B2 (es)
EP (2) EP1999133B1 (es)
JP (2) JP5430395B2 (es)
KR (2) KR101395377B1 (es)
CN (2) CN101448838B (es)
AP (2) AP2757A (es)
AU (1) AU2007245194B2 (es)
BR (1) BRPI0710199A2 (es)
CA (1) CA2647316C (es)
DK (1) DK1999133T3 (es)
EA (2) EA016140B1 (es)
ES (2) ES2430557T3 (es)
HR (2) HRP20080554B1 (es)
IL (2) IL194122A (es)
MX (1) MX2008012398A (es)
NO (2) NO342102B1 (es)
NZ (2) NZ571302A (es)
PL (1) PL1999133T3 (es)
PT (1) PT1999133E (es)
SG (1) SG170794A1 (es)
SI (1) SI1999133T1 (es)
UA (1) UA97241C2 (es)
WO (1) WO2007126812A2 (es)
ZA (1) ZA200808046B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
EP2528923B1 (en) 2010-01-28 2014-07-30 Mapi Pharma Limited Process for the preparation of darunavir and darunavir intermediates
CN102190638A (zh) * 2010-03-16 2011-09-21 中国科学院上海药物研究所 联芳基醇二胺类化合物、其药物组合物、制备方法及应用
CN102584748B (zh) * 2011-01-13 2015-02-11 浙江九洲药业股份有限公司 夫沙那韦中间体的制备方法
PL2702045T3 (pl) * 2011-04-26 2018-04-30 Mylan Laboratories Ltd. Nowy sposób sporządzania Etrawiryny
CN107266498B (zh) 2011-10-07 2023-10-03 吉利德科学公司 制备抗病毒核苷酸类似物的方法
EP2634180A1 (en) 2012-03-01 2013-09-04 Lonza Ltd. Enzymatic process for the preparation of butyrolactones
CN103664976B (zh) * 2013-12-12 2015-11-04 惠州市莱佛士制药技术有限公司 一种顺式六氢呋喃并[2,3-b]呋喃-3-醇的制备方法
US9936723B2 (en) 2014-02-12 2018-04-10 Senomyx, Inc. Process for the synthesis of substituted 1-benzyl-3-(1-(isoxazol-4-ylmethyl)-1h-pyrazol-4-yl)imidazolidine-2,4-diones
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
JP6435907B2 (ja) * 2015-02-16 2018-12-12 住友化学株式会社 ヘキサヒドロフロフラノール誘導体の製造方法
CN108610227B (zh) * 2016-12-10 2021-02-09 中国科学院大连化学物理研究所 一种制备双环芳香化合物的方法
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
EP3914604B1 (en) 2019-01-25 2026-03-04 Brown University Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026749A1 (en) 1993-05-14 1994-11-24 Merck & Co., Inc. Hiv protease inhibitors
AU1369001A (en) * 1995-12-13 2001-03-22 Abbott Laboratories Retroviral protease inhibiting compounds
EP2314563A3 (en) 1999-12-23 2012-04-04 Ampac Fine Chemicals LLC Improved preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
AU2002255473A1 (en) * 2000-10-24 2002-09-04 Glaxo Group Limited Process for preparing intermediates of hiv protease inhibitors
EP1436884A2 (en) 2001-07-20 2004-07-14 Koninklijke Philips Electronics N.V. Oscillating circuit, converter with such oscillating circuit, and preconditioner with such converter
WO2003091264A2 (en) * 2002-04-26 2003-11-06 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
US20050239054A1 (en) * 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
WO2005042773A1 (en) * 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds

Also Published As

Publication number Publication date
US8173623B2 (en) 2012-05-08
HRP20080554A2 (hr) 2009-02-28
PT1999133E (pt) 2013-10-16
US20080004242A1 (en) 2008-01-03
NZ571302A (en) 2011-11-25
PL1999133T3 (pl) 2014-01-31
AP2008004641A0 (en) 2008-10-31
US20110065631A1 (en) 2011-03-17
CA2647316A1 (en) 2007-11-08
EP1999133B1 (en) 2013-08-21
JP5430395B2 (ja) 2014-02-26
HK1180311A1 (en) 2013-10-18
EP2570416A1 (en) 2013-03-20
SG170794A1 (en) 2011-05-30
AU2007245194A1 (en) 2007-11-08
KR101429300B1 (ko) 2014-08-11
EP1999133A2 (en) 2008-12-10
KR20140021047A (ko) 2014-02-19
ES2430557T3 (es) 2013-11-21
JP2013082717A (ja) 2013-05-09
EP2570416B1 (en) 2016-03-16
US8431745B2 (en) 2013-04-30
NO20180086A1 (no) 2008-12-22
HRP20080554B1 (hr) 2014-11-21
NZ596074A (en) 2013-03-28
NO342102B1 (no) 2018-03-26
WO2007126812A2 (en) 2007-11-08
SI1999133T1 (sl) 2013-10-30
IL194122A (en) 2016-08-31
BRPI0710199A2 (pt) 2012-03-06
US20120258935A1 (en) 2012-10-11
NO20084547L (no) 2008-12-22
AU2007245194B2 (en) 2013-03-14
CN102516259A (zh) 2012-06-27
HK1126756A1 (en) 2009-09-11
JP2009531441A (ja) 2009-09-03
EA016140B1 (ru) 2012-02-28
MX2008012398A (es) 2008-12-17
AP2757A (en) 2013-09-30
HRP20140626A2 (hr) 2014-11-07
EA201100994A1 (ru) 2012-03-30
KR101395377B1 (ko) 2014-05-14
AP2013006690A0 (en) 2013-01-31
EA200802074A1 (ru) 2009-02-27
ZA200808046B (en) 2009-06-24
CA2647316C (en) 2013-05-28
DK1999133T3 (da) 2013-11-25
US20130172295A1 (en) 2013-07-04
EA020088B1 (ru) 2014-08-29
CN101448838A (zh) 2009-06-03
CN101448838B (zh) 2012-07-04
CN102516259B (zh) 2014-12-10
IL225167A (en) 2016-03-31
KR20080108322A (ko) 2008-12-12
WO2007126812A3 (en) 2007-12-21
NO342965B1 (no) 2018-09-10
UA97241C2 (uk) 2012-01-25

Similar Documents

Publication Publication Date Title
ES2572001T3 (es) Derivado de bisfurano antivírico como inhibidor de la proteasa del VIH e intermedios del mismo
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
CO2021008681A2 (es) Inhibidor de 15-pgdh
CL2012000573A1 (es) Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv.
EA201070182A1 (ru) Алкилсульфонилзамещённые тиазолидные соединения
ECSP099601A (es) Inhibidores de proteasa de serina
UY3723Q (es) Aerosol
EA201101620A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
ECSP088258A (es) Inhibidores de serina proteasas
CL2011002830A1 (es) Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
CO6220968A2 (es) Inhibidores heterociclicos de la aspartil proteasa
AR058433A1 (es) Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso
EA201100851A1 (ru) Аналоги нуклеозидов
UY32730A (es) Inhibidores de cyp17
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
ECSP11011065A (es) Composición farmacéutica de un potente inhibidor de hcv para su administración oral
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
EA200901109A1 (ru) Применение n-фениламидинов в качестве гербицидов
CO6351740A2 (es) Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido
UY31688A1 (es) Plaguicidas
CL2007001004A1 (es) Compuestos derivados peptidicos, inhibidores de proteasa, utiles para el tratamiento de una infeccion por el virus de la hepatitis c.
CO2022006965A2 (es) Inhibidores de egfr
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas
UY32408A (es) Macrolido anti-inflamatorio
AR093738A1 (es) Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos